Alemtuzumab effective for early MS, but has serious complications

3 November 2008 Print this article Comments Share this article
Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, is an effective treatment for early multiple sclerosis, but may cause serious autoimmunity related complications, a phase II trial shows....

Want to read complete article? Please Sign in or Register.